* Merck & Co Inc reported quarterly adjusted earnings of $2.07 per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $1.40. The mean expectation of eighteen analysts for the quarter was for earnings of $1.88 per share. Wall Street expected results to range from $1.76 to $2.12 per share.
* Revenue rose 8.9% to $15.78 billion from a year ago; analysts expected $15.20 billion.
* Merck & Co Inc's reported EPS for the quarter was $1.87.
* The company reported quarterly net income of $4.76 billion.
* Merck & Co Inc shares had fallen by 3.8% this quarter and gained 16.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 5.9% in the last three months.
* In the last 30 days, eleven analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Merck & Co Inc is $139.00 This summary was machine generated from LSEG data April 25 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 1.88 2.07 Beat
Dec. 31 2023 -0.11 0.03 Beat
Sep. 30 2023 1.95 2.13 Beat
Jun. 30 2023 -2.18 -2.06 Beat
Comments